---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091745"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:19:25.278341+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q2 net loss $12.5M; neffy PDUFA Oct 2; cash $218.7M

## Summary
- Cash, equivalents and short-term investments $218.7M as of June 30, 2024, providing at least three years of operating runway.
- Net loss $12.5M vs $17.4M in Q2 2023; R&D $6.9M, G&A $8.9M.
- neffy NDA under FDA review; draft physician labeling received; PDUFA target action date October 2, 2024.
- EURneffy received CHMP positive opinion; formal EU marketing authorization expected Q3 2024.
- Phase 2b outpatient study of neffy for urticaria on track to start dosing in Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-091745
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/0000950170-24-091745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/spry-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091745
- JSON: https://secwatch.observer/filing/0000950170-24-091745.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.